FDA Approves KOSELUGO — AstraZeneca Pharmaceuticals LP

# FDA Approves AstraZeneca's KOSELUGO (selumetinib) for Neurofibromatosis Type 1 AstraZeneca Pharmaceuticals LP has received FDA approval for KOSELUGO (selumetinib), an oral MEK inhibitor for neurofibromatosis type 1 (NF1), positioning the company to capture market share in the rare disease segment and potentially establishing a new treatment standard for a condition with limited therapeutic options. The approval expands AstraZeneca's oncology and rare disease portfolio while opening revenue opportunities